Drug Discovery@nature.com 6 January 2012

TABLE OF CONTENTS 6 January 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Reviews Drug Discovery Turns Ten Timely Content, Leading Authors, Enhanced Experience Access selected free content from Nature Reviews Drug Discovery to celebrate the 10th anniversary of this leading publication. www.nature.com/nrd/collections/10/index.html   News Top New neglected disease research scheme pools IP and expertise doi:10.1038/nrd3642 A new initiative launched by the World Intellectual Property Organization intends to pool intellectual property as well as intellectual capital to accelerate the discovery and development of new drugs, vaccines and diagnostics for neglected tropical diseases, malaria and tuberculosis. Full Text 2011 in reflection doi:10.1038/nrd3643 Last year saw an upturn in new drug approvals, the end of patent protection for the world's top-selling drug, continued regulatory negotiations and more. Full Text Market watch: Upcoming market catalysts in Q1 2012 doi:10.1038/nrd3632 Important catalysts include approval decisions on vismodegib for the treatment of adults with advanced basal cell carcinoma, and on peginesatide for anaemia associated with chronic kidney disease. Top-line Phase III data are also expected for tivozanib for the treatment of advanced renal cell carcinoma. Full Text Deal watch: High hopes for oral SYK inhibitor in rheumatoid arthritis doi:10.1038/nrd3631 Biogen Idec and Portola Pharmaceuticals have entered into a licensing agreement to develop and commercialize PRT062607, a novel oral spleen tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis as well as other autoimmune and inflammatory diseases. Full Text Analysis Top Splicing out BRAF′s resistance doi:10.1038/scibx.2011.1340 The discovery of a mechanism by which melanomas expressing mutant BRAF acquire resistance to targeted drugs gives companies a new resistance mechanism to screen against in the design of next-generation BRAF inhibitors and furthers the case for combining Zelboraf with downstream kinase inhibitors. Full Text Fresh from the Pipeline: Brentuximab vedotin doi:10.1038/nrd3629 In August 2011, brentuximab vedotin (Adcetris; Seattle Genetics), a CD30-specific antibody–drug conjugate, was approved by the US Food and Drug Administration for the treatment of patients with Hodgkin's lymphoma and patients with systemic anaplastic large cell lymphoma. Full Text From the analyst's couch: A decade of change doi:10.1038/nrd3630 Data on indicators such as the number and success rate of research and development projects illustrate trends in the pharmaceutical industry over the past decade. Full Text Research Highlights Top Vaccines: Enhancing glycan presentation increases vaccine efficacy doi:10.1038/nrd3637 By maximizing the presentation of carbohydrate epitopes to T cells, scientists have constructed a vaccine against group B streptococcus that is significantly more potent than currently available vaccines. Full Text Antiparasitic drugs: Two-pronged tactics for malaria control doi:10.1038/nrd3635 An academia–industry consortium has identified a new class of compounds that confer complete protection against parasite challenge in rodent models of malaria, as well as showing potent in vivo activity against blood-stage parasites. Full Text Epigenetics: Worth another look? doi:10.1038/nrc3187 Patients with non-small-cell lung cancer with tumours that have a specific subset of methylated genes might benefit from combined treatment with a low-dose DNA methyltransferase inhibitor and a histone deacetylase inhibitor. Full Text Research & Reviews Top The pharmacological landscape and therapeutic potential of serine hydrolases doi:10.1038/nrd3620 This article outlines the current state of pharmacology for mammalian serine hydrolases, including marketed drugs, compounds that are under clinical investigation and selective inhibitors emerging from academic probe development efforts. Full Text Cancer immunotherapy comes of age doi:10.1038/nature10673 Advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses, together with the advent of targeted therapies, suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients. Full Text Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons doi:10.1038/nature10726 Findings from a recent Nature study suggest a therapeutic strategy for reactivating the functional but dormant allele of Ube3a in patients with Angelman syndrome using topoisomerase inhibitors. Full Text Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential doi:10.1038/nm.2582 Antibodies that bind and inhibit activated matrix metalloproteinases 2 and 9 in a manner analogous to the mechanism of action of tissue inhibitors of metalloproteinases are therapeutically effective in mouse models of inflammatory bowel disease. Full Text Drug Discovery JOBS of the week Research Investigator in Oncology BeiGene Inc. Experienced researcher in Biological and Chemical Sciences (e.g. Biochemistry, Structural Biology, Pharmacology), with solid background and at least 4-years of relevant post-Ph.D. expertise University of Patras (Departments of Pharmacy, Medicine, Chemistry, Biology) Research Assistant - Student Worker Kelly Scientific Resources Computational Chemist University of Dundee Biostatistician CTC Clinical Trial Consulting More Science jobs from Drug Discovery EVENT Resolving Inflammation: Mechanisms and Drug Discovery 01.04.12 Oxford, UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement Miami 2012 Winter Symposium: Nanotechnology in Biomedicine February 26-29, 2012 • Miami, FL, USA The 45th Miami Winter Symposium will bring together leaders in the field to discuss breakthroughs in new nanomaterials and the challenges in translating these materials into products for the clinic and laboratory. For more information and to register, visit: www.nature.com/natureconferences/miami/mws2012   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.